This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

GARY L. FREED, MD, MPH
The Robert Wood Johnson Clinical Scholars Program The Cecil G. Sheps Center for Health Services Research Division of Community Pediatrics University of North Carolina at Chapel Hill CB 7490 Chase Hall Chapel Hill, NC 27599-7490

THOMAS R. KONRAD, PHD; GORDON H. DEFRIESE, PHD
The Cecil G. Sheps Center for Health Services Research

JACOB A. LOHR, MD
Division of Community Pediatrics University of North Carolina at Chapel Hill

Am J Dis Child. 1993;147(2):124-128.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Sir.—Haemophilus influenzae type b (Hib) infection in children is responsible for approximately 12 000 cases of meningitis and 7500 cases of other invasive diseases annually in the United States,^1,2 with a mortality rate of 5% in cases of meningitis and as many as 40% of survivors having significant neurologic sequelae.³

On October 4, 1990, the Food and Drug Administration (FDA) permitted one Hib vaccine manufacturer to amend its package insert to claim safety and efficacy for administration at age 2 months.⁴ The previous recommended age of first administration had been 15 months. The American Academy of Pediatrics (AAP) soon issued a recommendation for first administration to infants at age 2 months.

A letter called a Ped-Comm was sent from the AAP to its members in late October 1990 recommending the earlier age for first vaccination, but information on safety or efficacy was not included since . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?